Are hCV genotypes differently prone to the development of resistance to linear and macrocyclic protease inhibitors?
The high degree of HCV genetic variability makes HCV-genotypes, and even subtypes, differently prone to the development of PIs resistance-mutations. Overall, this can account for different responsiveness of HCV-genotypes to PIs, with important clinical implications in tailoring individualized and appropriate regimens.
In Asian Indians, low plasma adiponectin level was predictive of future development of diabetes.